ClinicalTrials.gg
Not yet recruitingNCT07937280ETMOPARKUpdated Nov 16, 2026

Effects of E-Tonus in Moderate Parkinson's Disease

An interventional study of Wrist-worn pulsed electromagnetic field (PEMF) stimulation device: active condition and Wrist-worn pulsed electromagnetic field (PEMF) stimulation device: sham condition in Moderate Parkinson Disease, sponsored by Brain and Mind. Not yet recruiting. Open to participants aged 50 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Brain and Mind · Not applicable, Interventional, and Supportive care

Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
50 Years to 75 Years
Sex
All
01

Study summary

The goal of this clinical trial is to evaluate the short-term effect of E-Tonus, a wrist-worn device that gives off a low-intensity pulsed electromagnetic field, on functional mobility in adults with moderate Parkinson's disease. It will also learn about the short-term safety profile of E-Tonus.

02

Conditions studied

  • Moderate Parkinson Disease

Browse trials for

03

In context

Parkinson Disease

4,578 studies on the registry are indexed under Parkinson Disease; 1,087 are open to participants now.

This study's planned enrollment of 40 is close to the median of 40 across 3,355 interventional studies indexed under Parkinson Disease.

Browse Parkinson Disease studies →

Lead sponsor

This is the only study on the registry with Brain and Mind as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 50-75 years;
  • Parkinson's disease (MDS diagnostic criteria)Hoehn \& Yahr stage II to II.5 confirmed in the ON medication state;
  • At least one of the following MDS-UPDRS criteria must be met, reflecting the presence of gait or balance impairment but still able to walk unaided:
  • MDS-UPDRS Gait (item 3.10) score = 2, OR
  • Freezing of gait (item 3.11) score ranging from 1 to 2, OR
  • Postural instability (item 3.12) score ranging from 1 to 2, OR
  • Walking \& Balance (item 2.12) score = 2, OR
  • Freezing (item 2.13) score ranging from 1 to 2;
  • Stable dopaminergic therapy ≥4 weeks;
  • Predictable ON-state duration ≥2 consecutive hours.

Exclusion criteria

Exclusion Criteria:

  • Severe axial motor impairment (pre-specified items rated 3 or 4) or investigator-judged fall/safety risk;
  • Pregnancy;
  • Electromagnetic ;
  • Postural hypotension, musculoskeletal, or vestibular disorders affecting balance;
  • Uncontrolled cardiac, pulmonary, major neurological, or metabolic disease;
  • Cognitive impairment ( ≤22);
  • Implanted active medical device (e.g., DBS, pacemaker) or metal implant/tattoo at the wrist application site;
  • History of radial nerve injury on the device-bearing arm;
  • Legally protected vulnerable adults.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Active E-Tonus

    Participants wear E-Tonus on the wrist in the active condition, emitting low-frequency, low-intensity pulsed electromagnetic field stimulation, for approximately 30 minutes. In this crossover study, all participants receive both the active and sham conditions during a single study visit, in a randomized order, separated by a 30-minute washout period. Assessments are performed in the ON medication state.

    Device: Wrist-worn pulsed electromagnetic field (PEMF) stimulation device: active condition · Device: Wrist-worn pulsed electromagnetic field (PEMF) stimulation device: sham condition

  • Sham comparator
    Sham E-Tonus

    Participants wear E-Tonus on the wrist in the sham condition, with no stimulation emitted, for approximately 30 minutes. The sham device is visually and physically indistinguishable from the active device. In this crossover study, all participants receive both the active and sham conditions during a single study visit, in a randomized order, separated by a 30-minute washout period. Assessments are performed in the ON medication state.

    Device: Wrist-worn pulsed electromagnetic field (PEMF) stimulation device: active condition · Device: Wrist-worn pulsed electromagnetic field (PEMF) stimulation device: sham condition

Interventions

  • DeviceWrist-worn pulsed electromagnetic field (PEMF) stimulation device: active condition

    Personal, portable, wrist-worn, non-invasive Class IIa electromagnetic stimulation device manufactured by A.F. Genese. It emits a low-frequency, low-intensity pulsed electromagnetic field with a controlled pulse width, delivering peripheral transcutaneous stimulation at the wrist. Used once, for approximately 30 minutes, during a single study visit, in addition to the participant's usual Parkinson's disease medication.

  • DeviceWrist-worn pulsed electromagnetic field (PEMF) stimulation device: sham condition

    The same wrist-worn device in a sham configuration that emits no electromagnetic field. It is visually and physically indistinguishable from the active device, so that participants and investigators remain blinded. Used once, for approximately 30 minutes, during a single study visit.

06

What researchers measure

Primary outcomes

  1. Change in instrumented Timed Up-and-Go (iTUG) 7-meter total task time: active vs. sham E-Tonus

    The iTUG test measures the time (in seconds) a participant needs to stand up from a chair, walk 7 meters, turn around, walk back and sit down again, from the start of the sit-to-stand transition to the end of the stand-to-sit transition. It is instrumented with an accelerometer. Two trials are performed at each time point and averaged. For each device condition (active and sham), the change from baseline to end-of-period is calculated. The outcome is the difference between active and sham conditions in this change. A greater reduction in time indicates better functional mobility.

    Time frame: Baseline (before each device condition) and end-of-period (after approximately 30 minutes of device use), for each of the 2 device conditions within a single study visit (Day 1)

  2. Incidence, severity, seriousness and relatedness of adverse events (AEs) and adverse device effects (ADEs)

    Number of participants with adverse events and adverse device effects, described by severity (mild, moderate, severe), seriousness (serious or non-serious) and relationship to the device as assessed by the investigator, by device condition (active and sham).

    Time frame: From the start of the first device application (Day 1) through 48 hours after the last device application

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No — There is no plan to share individual participant data. This is a small pilot investigation (40 participants), and the data are collected under French and European data protection regulations (GDPR), with participant consent limited to the purposes of this study. Aggregate results will be made available through scientific publication.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Apr 2027, 4 months later.

Of 1,294 non-industry interventional studies with no phase under Parkinson Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 4 months is below that.

Counting every sponsor, half of 1,370 studies reached it within 25 months; a quarter within 12 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 8, 2026
First posted
Nov 16, 2026
StartEst.
Dec 2026
Primary completionEst.
Apr 2027
CompletionEst.
Apr 2027
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07937280
Lead sponsor
Brain and Mind
Responsible party
Sponsor
First posted
Nov 16, 2026
Start date
Dec 2026 (estimated)
Primary completion
Apr 2027 (estimated)
Completion
Apr 2027 (estimated)
Last update
Nov 16, 2026

Study contacts

Senior Clinical Project Manager
Contact
clinical@brainandmind.fr
+33624358886
David DEVOS, Professor Neurologist
principal investigator · Service de Neurologie B : Neurologie vasculaire CHU de Lille - Hôpital Roger Salengro rue Emile Laine 59000 LILLE

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion